Related Experiment Videos
Proteinuria and cardiovascular disease.
1Department of Internal Medicine, Division of Nephrology, St. Louis Veterans Administration Medical Center, St. Louis, MO, USA. Wendy.brown@med.va.gov
Summary
Microalbuminuria and proteinuria are key indicators of kidney disease progression in diabetic and hypertensive patients. Early detection and intervention, including ACE inhibitors, can help slow kidney failure and reduce cardiovascular risks.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Microalbuminuria/proteinuria is an established independent risk factor for renal disease progression in diabetes and hypertension.
- Recent evidence highlights proteinuria as an independent risk factor for cardiovascular morbidity and mortality, even without overt kidney disease.
Purpose of the Study:
- To summarize the established role of proteinuria in renal disease and its emerging significance in cardiovascular health.
- To underscore the implications of proteinuria as a risk marker for cardiovascular disease.
Main Methods:
- Review of clinical and experimental data on proteinuria.
- Analysis of findings from clinical trials on angiotensin-converting enzyme inhibitors.
- Synthesis of recent evidence linking proteinuria to cardiovascular outcomes.
Main Results:
- Proteinuria predicts renal disease progression and cardiovascular events.
- Angiotensin-converting enzyme inhibitors can slow renal disease progression, independent of blood pressure control.
- Proteinuria is associated with a cluster of cardiovascular risk factors, including insulin resistance, hypertension, and dyslipidemia.
Conclusions:
- Proteinuria is a critical marker for both kidney and cardiovascular disease.
- Therapeutic interventions targeting proteinuria may delay kidney failure.
- Identifying and managing proteinuria is crucial for cardiovascular risk stratification and treatment.